Your browser doesn't support javascript.
Pre-existing Autoantibodies Neutralizing High Concentrations of Type I Interferons in Almost 10% of COVID-19 Patients Admitted to Intensive Care in Barcelona.
Solanich, Xavier; Rigo-Bonnin, Raúl; Gumucio, Victor-David; Bastard, Paul; Rosain, Jérémie; Philippot, Quentin; Perez-Fernandez, Xosé-Luis; Fuset-Cabanes, Maria-Paz; Gordillo-Benitez, Miguel-Ángel; Suarez-Cuartin, Guillermo; Boza-Hernandez, Enric; Riera-Mestre, Antoni; Parra-Martínez, Alba; Colobran, Roger; Antolí, Arnau; Navarro, Sergio; Rocamora-Blanch, Gemma; Framil, Mario; Calatayud, Laura; Corbella, Xavier; Casanova, Jean-Laurent; Morandeira, Francisco; Sabater-Riera, Joan.
  • Solanich X; Department of Internal Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain. xsolanich@bellvitgehospital.cat.
  • Rigo-Bonnin R; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain. xsolanich@bellvitgehospital.cat.
  • Gumucio VD; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Bastard P; Department of Clinical Laboratory, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Rosain J; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Philippot Q; Department of Intensive Care, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Perez-Fernandez XL; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, EU, France.
  • Fuset-Cabanes MP; Imagine Institute, University of Paris, Paris, EU, France.
  • Gordillo-Benitez MÁ; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Suarez-Cuartin G; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, EU, France.
  • Boza-Hernandez E; Imagine Institute, University of Paris, Paris, EU, France.
  • Riera-Mestre A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, EU, France.
  • Parra-Martínez A; Imagine Institute, University of Paris, Paris, EU, France.
  • Colobran R; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Antolí A; Department of Intensive Care, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Navarro S; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Rocamora-Blanch G; Department of Intensive Care, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Framil M; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Calatayud L; Department of Intensive Care, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Corbella X; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Casanova JL; Department of Respiratory Medicine, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
  • Morandeira F; Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
  • Sabater-Riera J; Department of Anesthesiology, Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
J Clin Immunol ; 41(8): 1733-1744, 2021 11.
Article in English | MEDLINE | ID: covidwho-1525558
ABSTRACT

BACKGROUND:

It is important to predict which patients infected by SARS-CoV-2 are at higher risk of life-threatening COVID-19. Several studies suggest that neutralizing auto-antibodies (auto-Abs) against type I interferons (IFNs) are predictive of critical COVID-19 pneumonia.

OBJECTIVES:

We aimed to test for auto-Abs to type I IFN and describe the main characteristics of COVID-19 patients admitted to intensive care depending on whether or not these auto-Abs are present.

METHODS:

Retrospective analysis of all COVID-19 patients admitted to an intensive care unit (ICU) in whom samples were available, from March 2020 to March 2021, in Barcelona, Spain.

RESULTS:

A total of 275 (70.5%) out of 390 patients admitted to ICU were tested for type I IFNs auto-antibodies (α2 and/or ω) by ELISA, being positive in 49 (17.8%) of them. Blocking activity of plasma diluted 1/10 for high concentrations (10 ng/mL) of IFNs was proven in 26 (9.5%) patients. Almost all the patients with neutralizing auto-Abs were men (92.3%). ICU patients with positive results for neutralizing IFNs auto-Abs did not show relevant differences in demographic, comorbidities, clinical features, and mortality, when compared with those with negative results. Nevertheless, some laboratory tests (leukocytosis, neutrophilia, thrombocytosis) related with COVID-19 severity, as well as acute kidney injury (17 [65.4%] vs. 100 [40.2%]; p = 0.013) were significantly higher in patients with auto-Abs.

CONCLUSION:

Auto-Abs neutralizing high concentrations of type I IFNs were found in 9.5% of patients admitted to the ICU for COVID-19 pneumonia in a hospital in Barcelona. These auto-Abs should be tested early upon diagnosis of SARS-CoV-2 infection, as they account for a significant proportion of life-threatening cases.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoantibodies / Interferon Type I / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Clin Immunol Year: 2021 Document Type: Article Affiliation country: S10875-021-01136-x

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Autoantibodies / Interferon Type I / Antibodies, Neutralizing / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study Limits: Aged / Female / Humans / Male / Middle aged Language: English Journal: J Clin Immunol Year: 2021 Document Type: Article Affiliation country: S10875-021-01136-x